IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer

Reuters

2025/11/19

IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer

IceCure Medical Ltd. has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584944461"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584944461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584944461?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584944461","market":"nz","top_or_hot":-1,"title":"IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICCM","symbol_name":"IceCure Medical Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL6yRvDb:1","article_id":"2584944461","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584944461","pubTimestamp":1763560493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IceCure Medical Ltd. has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense Cryoablation System for breast cancer and other indications, while XSense and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ICCM":"IceCure Medical Ltd.","BK4082":"医疗保健设备"},"translate_title":"IceCure Medical获得FDA批准ProSense冷冻消融系统治疗低风险乳腺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":0.9},"content_text":"IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n    \n\nIceCure Medical Ltd. has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}